Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

October 5, 2011

BSX Begins Stent Trial Enrollment

Natick-based medical device maker Boston Scientific Corp. announced that it has enrolled the first of 328 patients for a trial of a new stent for patients with coronary artery disease.

The trial for the Omega Platinum Chromium Bare-Metal Coronary Stent System will take place at 40 sites in the United States and Europe. The first patient was enrolled in Latvia.

The company will use the trial data to support approval of the investigational device by the U.S. Food and Drug Administration.

The stent is the third in BSX's line of platinum chromium stents, which offer greater radial strength and flexibility while reducing recoil, according to the company.

Sign up for Enews

WBJ Web Partners

0 Comments

Order a PDF